ArticleEye (London, England)2026
Incidence and characteristics of newly formed polypoidal lesions in polypoidal choroidal vasculopathy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the incidence of newly formed polypoidal lesions (PLs) and associated neovascular lesion changes in eyes with polypoidal choroidal vasculopathy (PCV) using optical coherence tomography angiography (OCTA).
methodsThe medical records of patients diagnosed with PCV who were treated with intravitreal anti-vascular endothelial growth factor therapy and followed up for at least 3 years were retrospectively reviewed. Patients were classified into a new PL group or no new PL group based on the development of new PLs on OCTA during the follow-up period. The primary outcome measures included the incidence of new PLs and changes in morphological characteristics (area and circularity) of the neovascular lesions.
resultsThe final analysis included 45 eyes from 45 patients. New PLs were observed in 15 (33.3%) eyes. The new PL group demonstrated a significantly greater increase in neovascular lesion area compared with the no new PL group (1.63 ± 0.54 mm² vs. 0.19 ± 0.54 mm²; P = 0.041). Furthermore, the new PL group exhibited a significant decline in neovascular lesion circularity compared with the no new PL group (-0.052 ± 0.040 vs. 0.029 ± 0.030; P = 0.004). Most new PLs (80%) were classified as de novo, defined as those developing in a location where no neovascular lesions were present at the previous visit.
conclusionNew PL formation frequently occurs in patients with PCV undergoing a treat-and-extend protocol. Expansion of the neovascular area and worsening of circularity have been identified as key precursors of new PL development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.